NCT03507088 is a NA clinical trial of Fluoroestradiol (18F) in Metastatic Breast Cancer, sponsored by Zhimin Shao.

Who is sponsoring NCT03507088?

NCT03507088 is sponsored by Zhimin Shao.

What drugs are being tested in NCT03507088?

Interventions in NCT03507088: Fluoroestradiol (18F).

What condition does NCT03507088 study?

NCT03507088 studies Metastatic Breast Cancer.

Is NCT03507088 still recruiting?

NCT03507088 is currently completed. Last updated 8 May 2019.

Last reviewed 2019-05-08 · How we verify

NCT03507088

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Determine the Utility of FES-PET in the Prediction of Response to Fulvestrant in Women With Estrogen Positive Metastatic Breast Cancer

Completed NA Last updated 8 May 2019

What this trial tests

NA trial testing Fluoroestradiol (18F) in Metastatic Breast Cancer in 36 participants. Completed in 1 July 2018.

Timeline

1 September 2015

Primary endpoint
1 July 2018

1 July 2018

Quick facts

Lead sponsor	Zhimin Shao
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	36
Start date	1 September 2015
Primary completion	1 July 2018
Estimated completion	1 July 2018
Sites	2 locations across China

Drugs / interventions tested

Fluoroestradiol (18F) — full drug profile →

Conditions studied

Metastatic Breast Cancer — all drugs for Metastatic Breast Cancer →

Sponsor

Zhimin Shao — full company profile →

Who can join

Adults 18 to 70, female only, with Metastatic Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Effects of fulvestrant on the ERs may be evaluable by molecular imaging using positron emission tomography with the ER-specific FES tracer. In this study we will determine the utility of FES-PET in the prediction of response to fulvestrant 500 mg in women with estrogen positive metastatic breast cancer

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

18F-FES PET/CT Influences the Staging and Management of Patients with Newly Diagnosed Estrogen Receptor-Positive Breast Cancer: A Retrospective Comparative Study with 18F-FDG PET/CT.
Liu C, Gong C, Liu S, Zhang Y, et al · · 2019 · cited 37× · PMID 31337657 · DOI 10.1634/theoncologist.2019-0096
The Predictive Value of Early Changes in 18 F-Fluoroestradiol Positron Emission Tomography/Computed Tomography During Fulvestrant 500 mg Therapy in Patients with Estrogen Receptor-Positive Metastatic Breast Cancer.
He M, Liu C, Shi Q, Sun Y, et al · · 2020 · cited 23× · PMID 32272493 · DOI 10.1634/theoncologist.2019-0561
Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for Prediction of Progression-Free Survival After Fulvestrant Therapy in Patients With HR+/HER2- Metastatic Breast Cancer.
Liu C, Xu X, Yuan H, Zhang Y, et al · · 2020 · cited 14× · PMID 33251143 · DOI 10.3389/fonc.2020.580277

Verify or expand the search:

Other trials of Fluoroestradiol (18F)

Trials testing the same drug.

NCT07314073 — [18F]FES PET/CT for the Detection of Distant Metastasis in Low-grade ER-positive Stage III Breast Cancer · Phase 2 · recruiting
NCT06695039 — Diagnostic Performance of [18F]FES PET/CT for Axillary LN Metastasis in ER-positive Breast Cancer · Phase 2 · completed

Other recruiting trials for Metastatic Breast Cancer

Currently open trials in the same condition.

NCT07524855 — A Study of HLD-0117 in Patients With Metastatic Breast Cancer · Phase 1 · recruiting
NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07340541 — Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies · Phase 2 · recruiting
NCT07233928 — Breast Cancer Organelle Properties and Protein Expression Atlas in the Three Immunohistochemical Subtypes of Breast Canc · NA · recruiting
NCT07347600 — A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, · recruiting

Other Zhimin Shao trials

Trials by the same sponsor.

NCT07245797 — A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Neoadjuvant Therapy With Inavolisib Plu · Phase 2 · not yet recruiting
NCT06612814 — PARP Inhibitor With CDK4/ 6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer · Phase 3 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03507088 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhimin Shao
Last refreshed: 8 May 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03507088.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing